lung
airway
affect
sever
patholog
import
inflamm
infect
cancer
biomark
patholog
similar
found
involv
organ
chapter
briefli
discuss
gener
issu
biomark
pulmonari
disord
list
tabl
biomark
lung
cancer
describ
chapter
low
lung
function
associ
increas
morbid
mortal
therefor
interest
identifi
biomark
associ
impair
lung
function
lung
function
fvc
panel
inflammatori
biomark
includ
cytokin
chemokin
adhes
molecul
crp
wbc
count
blood
sampl
analys
subject
age
year
kuhlmann
et
al
wbc
count
crp
found
relat
poorer
lung
function
doserel
associ
found
combin
wbc
count
crp
toward
wbc
toward
fvc
indic
combin
two
biomark
yield
inform
assess
one
one
analys
associ
system
inflamm
lung
function
oxid
stress
hallmark
variou
chronic
inflammatori
lung
diseas
increas
concentr
ro
lung
patient
reflect
elev
concentr
oxid
stress
marker
breath
airway
lung
tissu
blood
tradit
measur
biomark
involv
invas
procedur
procur
sampl
examin
affect
compart
patient
discomfort
noninvas
approach
measur
oxid
stress
investig
collect
exhal
breath
condens
ebc
noninvas
sampl
method
realtim
analysi
evalu
oxid
stress
biomark
lower
respiratori
tract
airway
biomark
oxid
stress
h
malondialdehyd
antioxid
glutathion
nitros
stress
nitratenitrit
nitros
speci
measur
ebc
oxid
stress
biomark
also
measur
variou
antioxid
diseas
prognosi
ebc
current
use
research
diagnost
tool
free
radic
research
yield
inform
redox
disturb
degre
type
inflamm
lung
expect
ebc
exploit
detect
specif
level
biomark
monitor
diseas
sever
respons
treatment
communityacquir
pneumonia
cap
one
common
reason
emerg
depart
despit
preval
mani
challeng
proper
diagnosi
manag
pneumonia
accur
time
gold
standard
differenti
bacteri
viral
diseas
limit
precis
risk
stratif
patient
ensur
appropri
siteofcar
decis
clinic
risk
score
pneumonia
sever
index
psi
confus
urea
respiratori
rate
blood
pressur
age
year
blood
biomark
differ
physiopatholog
pathway
use
predict
longterm
surviv
patient
cap
prospect
studi
patient
admit
cap
follow
year
cox
regress
model
well
area
receiv
oper
characterist
curv
auc
use
investig
associ
initi
risk
assess
allcaus
mortal
alan
et
al
initi
psi
score
excel
longterm
prognost
accuraci
stepwis
increas
mortal
per
risk
class
addit
inflammatori
proadrenomedullin
cardiac
proatrial
natriuret
peptid
blood
biomark
measur
upon
hospit
admiss
improv
prognost
capabl
psi
patholog
chang
sever
acut
respiratori
syndrom
sar
suggest
sar
sequela
associ
dysregul
cytokin
chemokin
product
studi
taiwan
show
cytokin
chemokin
profil
patient
sar
differ
markedli
patient
communityacquir
pneumonia
cap
control
group
chien
et
al
serum
level
three
cytokin
significantli
elev
sar
patient
versu
cap
interleukin
il
cytokin
level
began
rise
develop
chest
involv
peak
earlier
lung
injuri
assess
chest
xray
convers
cap
patient
sar
patient
control
level
elev
rose
tandem
radiograph
chang
differ
group
ratio
sar
patient
versu
cap
patient
howev
set
patient
level
correl
strongli
sever
lung
injuri
earli
induct
well
subsequ
overproduct
lack
probabl
contribut
main
immunopatholog
process
involv
sar
lung
injuri
may
earli
biomark
lung
injuri
find
differ
observ
subject
cap
plasma
biomark
relat
inflamm
enhanc
neutrophil
recruit
lung
independ
associ
increas
mortal
patient
ali
higher
level
independ
predict
death
mcclintock
et
al
addit
lower
level
coagul
marker
protein
c
independ
associ
increas
risk
death
associ
lower
protein
c
level
nonsurvivor
continu
support
role
disord
coagul
aliard
associ
exist
despit
consist
use
lung
protect
ventil
persist
even
control
clinic
factor
also
impact
upon
outcom
two
biomark
independ
associ
mortal
need
studi
potenti
valu
stratifi
patient
clinic
trial
acut
respiratori
distress
syndrom
ard
rapid
onset
respiratori
failur
inabl
adequ
oxygen
blood
often
occur
critic
ill
acut
lung
injuri
ali
preced
ard
sever
respiratori
ill
progress
condit
lifethreaten
largescal
multicent
trial
patient
ard
ali
higher
level
nitric
oxid
urin
strongli
associ
improv
surviv
ventilatorfre
day
decreas
rate
organ
failur
mcclintock
et
al
author
specul
benefici
effect
ali
sinc
scaveng
oxygen
free
radic
gener
oxid
stress
sinc
increas
microcircul
help
better
perfus
tissu
bed
lung
investig
offer
altern
hypothesi
explain
find
creat
insid
bodi
may
benefici
effect
organ
lung
ali
might
help
prevent
tissu
damag
improv
oxygen
nutrient
deliveri
tissu
help
decreas
amount
toxic
oxygen
speci
author
also
specul
might
antibacteri
effect
could
import
infecti
condit
predispos
patient
ali
pulmonari
surfact
complex
lipid
protein
function
keep
alveoli
collaps
expir
surfact
protein
spa
spd
belong
collectin
famili
play
pivot
role
innat
immun
lung
pulmonari
collectin
directli
bind
broad
specif
varieti
microorgan
possess
antimicrobi
effect
protein
also
exhibit
inflammatori
antiinflammatori
function
collectin
enhanc
phagocytosi
microb
macrophag
opson
andor
nonopson
activ
protein
stimul
cell
surfac
express
phagocyt
receptor
includ
scaveng
receptor
mannos
receptor
sinc
express
spa
spd
abund
restrict
within
lung
protein
clinic
use
biomark
lung
diseas
level
spa
spd
bronchoalveolar
lavag
fluid
amniot
fluid
tracheal
aspir
pleural
effus
reflect
alter
alveolar
compart
epithelium
lung
matur
determin
spa
spd
sera
noninvas
use
tool
understand
patholog
chang
lung
diseas
includ
pulmonari
fibrosi
collagen
vascular
diseas
complic
interstiti
lung
diseas
pulmonari
alveolar
proteinosi
acut
respiratori
distress
syndrom
radiat
pneumon
takahashi
et
al
interstiti
lung
diseas
ild
defin
restrict
lung
function
impair
radiograph
sign
ild
mucin
highmolecular
weight
glycoprotein
express
type
ii
pneumonocyt
potenti
biomark
ild
retrospect
crosssect
analysi
caucasian
patient
polymyos
pm
dermatomyos
dm
ild
shown
elev
serum
level
compar
patient
without
ild
fathi
et
al
cutoff
level
uml
sensit
specif
diagnosi
ild
respect
level
serum
may
serv
measur
ild
patient
pmdm
promis
biomark
use
clinic
practic
assess
respons
treatment
chronic
obstruct
pulmonari
diseas
copd
consist
two
main
form
chronic
bronchiti
emphysema
suffer
usual
combin
condit
increas
interest
use
pulmonari
biomark
understand
monitor
inflamm
respiratori
tract
patient
copd
bronchial
biopsi
bronchoalveolar
lavag
provid
valuabl
inform
inflammatori
cell
mediat
procedur
invas
repeat
measur
limit
sputum
provid
consider
inform
inflammatori
process
includ
mediat
proteinas
copd
sampl
usual
repres
proxim
airway
may
reflect
inflammatori
process
distal
bronchi
analysi
exhal
breath
noninvas
procedur
repeat
measur
possibl
variabl
high
assay
rel
littl
inform
biomark
relat
clinic
outcom
progress
diseas
sever
diseas
clinic
subtyp
respons
therapi
inform
also
need
variabl
measur
futur
pulmonari
biomark
may
use
predict
diseas
progress
indic
diseas
instabl
predict
respons
current
therapi
novel
therapi
mani
develop
copd
foundat
biomark
qualif
consortium
cbqc
uniqu
publicpriv
partnership
establish
copd
foundat
pharmaceut
industri
academ
copd
expert
advisor
us
nation
heart
lung
blood
institut
fda
miller
et
al
initi
intent
cbqc
integr
data
collect
submit
dossier
qualif
led
fda
qualif
plasma
fibrinogen
prognost
enrich
biomark
allcaus
mortal
copd
exacerb
first
biomark
drug
develop
tool
qualifi
use
copd
fda
drug
develop
tool
qualif
program
aat
plasma
glycoprotein
inhibit
neutrophil
elastas
individu
inherit
alter
aat
gene
result
defici
protein
high
risk
copd
liver
cirrhosi
defici
detect
serum
protein
pattern
studi
past
test
defici
done
retrospect
patient
copd
liver
diseas
introduct
homeadminist
fingerstick
blood
spot
test
aat
genotyp
enabl
affect
famili
construct
pedigre
enabl
identifi
children
risk
develop
copd
later
life
avoid
exposur
dust
smoke
extracellular
matrix
ecm
remodel
lung
tissu
releas
protein
fragment
blood
may
detect
serolog
surrog
biomark
diseas
activ
copd
associ
ecm
turnov
sever
outcom
copd
assess
prospect
observ
multicent
studi
global
initi
chronic
obstruct
lung
diseas
grade
ii
iv
serum
sampl
analyz
stabl
state
exacerb
well
week
exacerb
stolz
et
al
result
show
patient
lowest
level
proform
collagen
type
iii
type
vi
sever
airflow
limit
hyperinfl
air
trap
emphysema
collagen
type
iii
collagen
type
vi
associ
dyspnea
conclus
serum
biomark
ecm
turnov
significantli
associ
diseas
sever
clinic
relev
outcom
patient
copd
lung
ecm
remodel
healthi
control
copd
patient
investig
copdgen
studi
data
suggest
type
vi
collagen
turnov
elastin
degrad
neutrophil
elastas
associ
copdinduc
inflamm
eosinophilbronch
emphysema
bihlet
et
al
serolog
assess
type
vi
collagen
elastin
turnov
may
assist
identif
phenotyp
like
associ
progress
amen
precis
medicin
clinic
trial
lung
failur
also
term
lung
attack
common
organ
failur
seen
intens
care
unit
lung
attack
effect
individu
copd
among
lead
caus
visit
emerg
room
among
chronic
diseas
suffer
caus
neuromuscular
impair
pulmonari
edema
pneumonia
vascular
diseas
acut
chronic
pulmonari
embol
patient
admit
hospit
sever
lung
failur
usual
take
month
get
baselin
health
patient
health
poor
start
new
attack
devast
even
fatal
test
could
accur
present
patient
diseas
could
make
easier
predict
treat
copd
progress
lung
failur
need
test
could
perform
clinic
lab
could
use
far
wide
current
lung
function
test
perform
certain
center
special
train
personnel
canada
prevent
organ
failur
proof
center
excel
vancouv
receiv
fund
genom
british
columbia
develop
biomarkerbas
test
determin
copd
patient
risk
lung
attack
gene
protein
biomark
set
discov
proof
center
could
abil
predict
copdcaus
lung
attack
need
valid
circul
bnp
level
evalu
paramet
presenc
sever
pulmonari
hypertens
ph
patient
chronic
lung
diseas
leucht
et
al
followup
time
approxim
year
signific
pulmonari
hypertens
mean
pulmonari
arteri
pressur
mm
hg
diagnos
onefourth
patient
led
decreas
exercis
toler
life
expect
elev
bnp
concentr
identifi
signific
pulmonari
hypertens
sensit
specif
predict
mortal
moreov
bnp
serv
risk
factor
death
independ
lung
function
impair
hypoxemia
conclud
plasma
bnp
facilit
noninvas
detect
signific
ph
high
accuraci
use
screen
test
presenc
ph
addit
bnp
enabl
assess
relev
ph
could
serv
use
prognost
paramet
chronic
lung
diseas
studi
reveal
serum
level
neuroendocrin
activ
biomark
chromagranin
cga
increas
male
smoker
impair
lung
function
associ
respiratori
symptom
degre
airway
obstruct
sorhaug
et
al
subgroup
airway
epitheli
cell
belong
diffus
neuroendocrin
system
term
pulmonari
neuroendocrin
cell
may
repres
put
regulatori
function
cga
prohormon
consid
control
growth
develop
fetal
lung
regul
ventil
circul
may
also
role
pathogenesi
smokinginduc
airway
diseas
find
indic
neuroendocrin
activ
may
import
smokingrel
airway
inflamm
remodel
rais
possibl
cga
could
predict
valu
biomark
prognosi
smokingassoci
diseas
measur
creactiv
protein
crp
biomark
inflamm
provid
increment
prognost
inform
beyond
achiev
tradit
biomark
patient
mild
moder
copd
may
enabl
accur
detect
patient
high
risk
mortal
lung
function
declin
significantli
relat
crp
level
averag
predict
chang
highest
lowest
quintil
howev
respiratori
caus
mortal
significantli
relat
crp
level
genomewid
express
profil
peripher
blood
sampl
subject
signific
airflow
obstruct
perform
find
noninvas
gene
express
biomark
copd
bhattacharya
et
al
correl
gene
express
lung
function
measur
identifi
set
gene
total
biomark
show
evid
signific
correl
quantit
trait
differenti
express
case
control
comparison
peripher
gene
express
biomark
previous
identifi
lung
tissu
cohort
reveal
two
gene
napepld
decreas
copd
case
compar
control
lung
tissu
blood
result
contribut
understand
gene
express
chang
peripher
blood
patient
copd
may
provid
insight
potenti
mechan
involv
diseas
patient
copd
often
high
risk
earli
death
identif
prognost
biomark
may
aid
improv
surviv
provid
earli
intens
therapi
highrisk
patient
studi
investig
prognost
role
hyperuricemia
baselin
prognosi
patient
copd
retrospect
evalu
data
hyperuricemia
found
associ
baselin
characterist
patient
copd
kaplanmei
surviv
curv
show
patient
copd
hyperuricemia
higher
risk
mortal
compar
patient
normouricemia
thu
hyperuricemia
promis
biomark
earli
mortal
patient
copd
decreas
express
vascular
endotheli
growth
factor
vegf
receptor
implic
pathogenesi
copd
level
placenta
growth
factor
plgf
anoth
angiogen
factor
increas
serum
bronchoalveolar
lavag
bal
fluid
patient
copd
invers
correl
cheng
et
al
serum
level
plgf
patient
copd
doubl
smoker
nonsmok
without
copd
find
suggest
bronchial
epitheli
cell
express
plgf
may
contribut
pathogenesi
copd
plgf
vegf
express
level
increas
cultur
bronchial
epitheli
cell
expos
proinflammatori
cytokin
although
mechan
underli
observ
detriment
effect
plgf
remain
clarifi
persist
plgf
express
might
advers
effect
lung
parenchyma
downregul
angiogenesi
although
aim
manag
patient
asthma
control
symptom
prevent
exacerb
morbid
diseas
optim
manag
may
requir
assess
monitor
biomark
ie
object
measur
lung
dysfunct
inflamm
clinic
observ
suggest
rhinoviru
infect
induc
specif
inflammatori
respons
predispos
individu
result
worsen
asthmat
symptom
increas
airway
inflamm
studi
shown
protein
ip
specif
releas
acut
virusinduc
asthma
measur
serum
predict
viral
trigger
acut
exacerb
wark
et
al
primari
bronchial
epitheli
cell
model
rhinoviru
infect
use
identifi
mediat
rhinoviru
infect
respond
infect
releas
high
level
rant
well
smaller
amount
perhap
combin
might
use
clinic
marker
identifi
rhinoviru
virusinduc
acut
asthma
addit
find
suggest
receptor
highli
express
activ
cell
might
role
worsen
airflow
obstruct
airway
inflamm
may
therefor
potenti
therapeut
target
intern
guidelin
manag
asthma
support
earli
introduct
corticosteroid
control
symptom
improv
lung
function
reduc
airway
inflamm
howev
individu
respond
corticosteroid
extent
would
desir
abl
predict
respons
corticosteroid
treatment
sever
biomark
assess
follow
treatment
corticosteroid
includ
measur
lung
function
peripher
blood
sputum
indic
inflamm
exhal
gase
breath
condens
wide
examin
measur
predict
respons
corticosteroid
airway
hyperrespons
exhal
eno
induc
sputum
sputum
eosinophilia
demonstr
best
predictor
shortterm
respons
corticosteroid
importantli
direct
treatment
normal
sputum
eosinophil
count
substanti
reduc
sever
exacerb
widespread
util
sputum
induct
hamper
procedur
rel
labor
intens
measur
eno
simpler
incorpor
assess
asthma
manag
strategi
led
reduct
exacerb
rate
challeng
either
simplifi
measur
sputum
eosinophilia
identifi
anoth
inflammatori
marker
similar
efficaci
sputum
eosinophil
count
predict
shortand
longterm
respons
corticosteroid
airway
inflamm
associ
increas
express
releas
inflammatori
reactant
regul
process
cell
migrat
activ
degranul
one
studi
done
quantifi
bronchial
lavag
bal
fluid
serum
level
secretori
leukocyt
proteas
inhibitor
slpi
solubl
intracellular
adhes
surrog
marker
inflammatori
immun
respons
asthma
copd
patient
similar
diseas
durat
time
holland
et
al
biomark
measur
use
commerci
avail
elisa
kit
find
show
four
measur
biomark
bal
higher
copd
patient
compar
asthma
sever
asthma
character
elev
level
proinflammatori
cytokin
neutrophil
inflamm
airway
blood
cytokin
biomark
system
inflamm
may
featur
increas
inflamm
sever
asthma
one
studi
found
level
higher
sever
asthmat
mildmoder
asthmat
control
conjunct
augment
circul
neutrophil
suggest
involv
neutrophilderiv
cytokin
pattern
silvestri
et
al
furthermor
patient
sever
asthma
level
posit
correl
exhal
nitric
oxid
circul
neutrophil
count
cytokin
level
elev
even
though
patient
highdos
inhal
steroid
find
might
reflect
inabl
drug
significantli
suppress
product
cytokin
airway
cellular
sourc
includ
epitheli
cell
inflammatori
cell
patient
sever
asthma
may
imbal
product
block
capac
autoantibodi
find
studi
may
clinic
relev
suggest
drug
block
releas
activ
might
repres
new
treatment
option
sever
asthma
airway
hyperrespons
main
featur
asthma
defin
increas
eas
degre
airway
narrow
respons
brochoconstrictor
stimuli
inflamm
play
central
role
pathogenesi
asthma
much
attribut
helper
cell
type
cytokin
activ
degre
strongli
correl
diseas
sever
one
inflammatori
mediat
asthma
nitric
oxid
exhal
level
elev
asthma
particularli
allerg
asthma
pollen
season
predict
asthma
exacerb
may
clinic
use
compar
exhal
valu
subject
previou
valu
compar
popul
base
normal
rang
cough
variant
asthma
cva
atop
cough
present
bronchodilatorresist
nonproduct
cough
may
differenti
caus
chronic
nonproduct
cough
measur
exhal
exhal
level
patient
atop
cough
significantli
lower
patient
cva
bronchial
asthma
fujimura
et
al
signific
differ
exhal
level
patient
cva
bronchial
asthma
uk
studi
find
show
feasibl
measur
bronchial
flux
concentr
j
alveolar
concentr
c
alv
children
c
alv
level
potenti
reflect
alveolar
inflamm
asthma
paraskaki
et
al
c
alv
j
measur
fraction
exhal
feno
multipl
exhal
flow
rate
asthmat
children
although
feno
jno
give
essenti
inform
c
alv
higher
asthmat
children
normal
children
studi
also
highlight
relationship
poor
control
asthma
c
alv
biomark
alveolar
inflamm
work
need
confirm
relev
novel
nanosensor
detect
possibl
asthma
attack
begin
minut
sensor
fit
handheld
devic
person
blow
devic
measur
content
breath
use
devic
would
provid
asthma
suffer
simpl
cost
effect
way
monitor
asthma
inflamm
explan
increas
level
exhal
nonenzymat
gener
nitrit
due
airway
acidif
asthmat
reduc
arginin
avail
may
also
contribut
lung
injuri
promot
format
cytotox
radic
peroxynitrit
arginin
level
declin
nitric
oxid
synthas
no
begin
gener
superoxid
lieu
therebi
favor
consumpt
via
gener
peroxynitrit
could
induc
lung
injuri
reduct
bioavail
via
format
speci
peroxynitrit
could
amplifi
rapid
loss
sod
activ
asthmat
respons
plasma
arginas
activ
declin
significantli
treatment
improv
symptom
addit
studi
need
determin
whether
measur
plasma
arginas
activ
provid
use
biomark
underli
metabol
disord
efficaci
treatment
diseas
arginas
activ
present
serum
probabl
accur
reflect
whole
bodi
arginas
activ
compartment
lung
sinc
arginas
intracellular
enzym
arginas
induc
monocyt
respons
helper
cell
type
cytokin
specul
cell
one
like
sourc
elev
arginas
serum
consist
local
arginas
express
within
macrophag
lung
athough
exhal
clinic
use
biomark
eosinophil
airway
inflamm
asthma
signific
valid
investig
requir
exhal
breath
condens
could
util
make
decis
clinic
practic
simpson
wark
endothelin
proinflammatori
profibrot
bronchoand
vasoconstrict
peptid
play
import
role
develop
airway
inflamm
remodel
asthma
studi
evalu
level
exhal
breath
condens
ebc
asthmat
differ
degre
asthma
sever
zietkowski
et
al
concentr
ebc
asthmat
patient
significantli
higher
healthi
volunt
level
significantli
higher
patient
unstabl
asthma
two
group
stabl
diseas
thu
measur
ebc
may
provid
anoth
use
diagnost
tool
detect
monitor
inflamm
patient
asthma
releas
bronchial
epithelium
influenc
mani
inflammatori
cell
essenti
asthma
interact
cytokin
may
play
import
role
increas
airway
inflamm
observ
postexercis
bronchoconstrict
asthmat
patient
ige
play
central
role
pathophysiolog
asthma
two
essenti
phase
pathophysiolog
sensit
allergen
clinic
express
symptom
reexposur
sensit
allergen
omalizumab
xolair
genentech
recombin
human
monoclon
antiig
antibodi
bind
circul
ige
regardless
allergen
specif
form
small
biolog
inert
igeantiig
complex
without
activ
complement
cascad
reduct
free
serum
ige
ie
ige
bound
omalizumab
occur
soon
administr
omalizumab
low
level
persist
throughout
treatment
appropri
dose
total
serum
ige
level
measur
patient
consid
treatment
omalizumab
dose
omalizumab
determin
basi
ige
level
bodi
weight
dose
base
estim
amount
drug
requir
reduc
circul
free
ige
level
less
iu
per
millilit
lebrikizumab
roch
inject
human
mab
design
block
contribut
key
featur
asthma
lebrikizumab
improv
lung
function
adult
asthma
patient
unabl
control
diseas
inhal
corticosteroid
induc
bronchial
epitheli
cell
secret
periostin
matricellular
protein
increas
level
periostin
biomark
asthma
measur
blood
milli
phase
ii
trial
patient
high
pretreat
periostin
level
greater
improv
lung
function
treat
lebrikizumab
compar
patient
low
periostin
level
corren
et
al
primari
endpoint
trial
show
week
lebrikizumabtr
patient
greater
increas
lung
function
baselin
compar
placebo
lebrikizumabtr
patient
highperiostin
subgroup
experienc
rel
increas
baselin
forc
expiratori
volum
second
compar
placebo
lowperiostin
subgroup
patient
drug
experienc
rel
increas
compar
placebo
result
support
investig
lebrikizumab
person
medicin
patient
suffer
moder
sever
uncontrol
asthma
periostin
enabl
select
patient
benefit
drug
cystic
fibrosi
cf
common
seriou
genet
diseas
among
caucasian
us
diseas
result
defect
gene
affect
multipl
aspect
cellular
function
seriou
symptom
buildup
thick
sticki
mucu
airway
lead
fatal
lung
infect
usual
method
screen
diagnosi
genotyp
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
mutat
antibodi
microarray
develop
platform
identifi
cfspecif
serum
proteom
signatur
serum
sampl
cf
patient
pool
compar
equival
pool
control
sera
order
identifi
pattern
protein
express
uniqu
cf
set
significantli
differenti
express
protein
enrich
protein
mediat
inflamm
nfkappab
signal
pathway
protein
may
select
express
cfaffect
tissu
lung
intestin
sever
instanc
data
antibodi
microarray
valid
quantit
analysi
revers
captur
protein
microarray
conclus
antibodi
microarray
technolog
sensit
quantit
robust
use
proteom
platform
discrimin
sera
cf
control
patient
saliva
noninvas
collect
process
show
great
potenti
biolog
fluid
cf
monitor
extens
protein
degrad
differenti
express
protein
identifi
sputum
biomark
inflamm
relat
pulmonari
exacerb
cf
use
fiber
microarray
measur
signific
variat
level
six
protein
saliva
supernat
vegf
egf
well
correl
level
clinic
assess
demonstr
valu
saliva
cf
research
monitor
nie
et
al
